Middle East and Africa Adalimumab Market Analysis, Insight, & Scope for Expand to Latest Development by 2029
Adalimumab, which was first licensed in the United States, is now available in more than 60 countries. Its Middle East and Africa market is consolidated, with only a few firms attempting to outsmart one other on price. Most of the major players are currently concentrating their efforts on the development of adalimumab biosimilars for the treatment of rheumatoid arthritis and psoriasis. This is seen in clinical trials testing the safety and efficacy of adalimumab biosimilars in the treatment of medical disorders.
